Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
Authors
Keywords
-
Journal
JAMA Internal Medicine
Volume 181, Issue 8, Pages 1043
Publisher
American Medical Association (AMA)
Online
2021-06-28
DOI
10.1001/jamainternmed.2021.2488
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overlap Weighting
- (2020) Laine E. Thomas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
- (2020) Björn Pasternak et al. BMJ-British Medical Journal
- TEMPORARY REMOVAL: Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: Evidence-based advances in monitoring and treatment
- (2020) Ian H. de Boer et al. KIDNEY INTERNATIONAL
- Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
- (2020) Shun Kohsaka et al. Lancet Diabetes & Endocrinology
- Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events
- (2020) Yan Xie et al. DIABETES CARE
- Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases
- (2020) Yan Xie et al. DIABETES CARE
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
- (2020) Kristian B Filion et al. BMJ-British Medical Journal
- Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D
- (2020) Colette DeJong et al. JAMA Internal Medicine
- Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19
- (2020) Benjamin Bowe et al. Clinical Journal of the American Society of Nephrology
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimates of the 2016 global burden of kidney disease attributable to ambient fine particulate matter air pollution
- (2019) Benjamin Bowe et al. BMJ Open
- Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study
- (2019) Yan Xie et al. BMJ-British Medical Journal
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study
- (2019) Björn Pasternak et al. BMJ-British Medical Journal
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
- (2019) Subodh Verma AMERICAN JOURNAL OF CARDIOLOGY
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Unknown
- (2018) DIABETES OBESITY & METABOLISM
- SGLT-2 Inhibitors and Cardiovascular Risk
- (2018) Matthew A. Cavender et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus
- (2018) Yan Xie et al. KIDNEY INTERNATIONAL
- Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts
- (2018) Ramón Estruch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved adherence adjustment in the Coronary Drug Project
- (2018) Eleanor J. Murray et al. Trials
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury
- (2017) Yan Xie et al. KIDNEY INTERNATIONAL
- Per-Protocol Analyses of Pragmatic Trials
- (2017) Miguel A. Hernán et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans
- (2017) Yan Xie et al. BMJ Open
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD
- (2016) Y. Xie et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-dimensional propensity score algorithm in comparative effectiveness research with time-varying interventions
- (2015) Romain Neugebauer et al. STATISTICS IN MEDICINE
- Use of Antidiabetic Drugs in the U.S., 2003–2012
- (2014) Christian Hampp et al. DIABETES CARE
- Beyond the intention-to-treat in comparative effectiveness research
- (2011) Miguel A Hernán et al. Clinical Trials
- Negative Controls
- (2010) Marc Lipsitch et al. EPIDEMIOLOGY
- High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data
- (2009) Sebastian Schneeweiss et al. EPIDEMIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started